Phathom Pharmaceuticals, Inc. PHAT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $204.89M+150% | $175.11M+217% | $147.19M+460% | $114.04M+1,050% | $81.86M+3,056% | ||
| $30.87M+174% | $22.6M+183% | $18.77M+334% | $14.93M+658% | $11.27M+1,801% | ||
| $174.02M+147% | $152.51M+223% | $128.42M+485% | $99.11M+1,147% | $70.59M+3,428% | ||
| 84.9%-1.3pp | 87.1%+1.5pp | 87.2%+3.7pp | 86.9%+6.8pp | 86.2%+9.1pp | ||
| $31.37M-7.3% | $32.78M-3.8% | $33.87M-12.9% | $35.54M-16.3% | $33.84M-29.3% | ||
| $239.25M-26.0% | $279.72M-3.8% | $308.03M+13.7% | $332.57M+52.4% | $323.13M+100% | ||
| $270.62M-24.2% | $312.5M-3.8% | $341.9M+10.3% | $368.11M+41.2% | $356.96M+70.6% | ||
| -$96.6M+66.3% | -$159.99M+42.3% | -$213.48M+25.9% | -$269M-6.4% | -$286.38M-38.2% | ||
| -47.1%+303pp | -91.4%+411pp | -145%+951pp | -235.9%+2,313pp | -349.8%+7,637pp | ||
| $65.84M-9.7% | $68.12M-5.4% | $70.29M+5.8% | $72.67M+25.1% | $72.91M+46.1% | ||
| -$60.7M-2.2% | -$61.26M-7.7% | -$61.08M-18.5% | -$61.15M-38.0% | -$59.41M-50.6% | ||
| -$157.3M+54.5% | -$221.25M+33.8% | -$274.55M+19.1% | -$330.15M-11.1% | -$345.79M-40.2% | ||
| -76.8%+346pp | -126.3%+479pp | -186.5%+1,106pp | -289.5%+2,706pp | -422.4%+9,085pp | ||
| -$2.10+59.5% | -$3.04+42.6% | -$3.77+34.4% | -$4.68+9.8% | -$5.19-16.1% | ||
| -$96.03M+66.4% | -$159.35M+42.4% | -$212.78M+25.9% | -$268.27M-6.4% | -$285.62M-38.3% | ||
| -46.9%+302pp | -91%+410pp | -144.6%+948pp | -235.2%+2,306pp | -348.9%+7,614pp | ||
| -$96.6M+66.3% | -$159.99M+42.3% | -$213.48M+25.9% | -$269M-6.4% | -$286.38M-38.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) generated $204.9M in revenue over the trailing twelve months, up 150.3% year over year.
- Is Phathom Pharmaceuticals, Inc. profitable?
- Phathom Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months, a -76.8% net margin.
- What are Phathom Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 84.9% and operating margin is -47.1%, with a -76.8% net margin.
- What is Phathom Pharmaceuticals, Inc.'s earnings per share?
- Phathom Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.10.
- Where does Phathom Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
